JP2011509263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509263A5 JP2011509263A5 JP2010541680A JP2010541680A JP2011509263A5 JP 2011509263 A5 JP2011509263 A5 JP 2011509263A5 JP 2010541680 A JP2010541680 A JP 2010541680A JP 2010541680 A JP2010541680 A JP 2010541680A JP 2011509263 A5 JP2011509263 A5 JP 2011509263A5
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- mmol
- carboxylic acid
- methyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C**(*)c(c(*(*)C*(C)*)c1*)c(*)c(*)c1N(C1=O)N=C(C)C1=NNc1c(*)c(*)c(*)c(*)c1O* Chemical compound C**(*)c(c(*(*)C*(C)*)c1*)c(*)c(*)c1N(C1=O)N=C(C)C1=NNc1c(*)c(*)c(*)c(*)c1O* 0.000 description 8
- DVNVHYZCRZPUIM-UHFFFAOYSA-N CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 Chemical compound CC1(C)c2cc(N3N=C(C)CC3=O)ccc2CC1 DVNVHYZCRZPUIM-UHFFFAOYSA-N 0.000 description 3
- LVQZRICCCFSHGG-UHFFFAOYSA-N Cc(cc1N)cc(-c2cccc(C(O)=O)c2)c1O Chemical compound Cc(cc1N)cc(-c2cccc(C(O)=O)c2)c1O LVQZRICCCFSHGG-UHFFFAOYSA-N 0.000 description 3
- ZNVWJXCMHYXFDF-SLMZUGIISA-N CC(/C(/C1=O)=N/Nc(cccc2-c3c[nH]c(C(O)=O)c3)c2O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3c[nH]c(C(O)=O)c3)c2O)=NN1c1cc(CCCC2)c2cc1 ZNVWJXCMHYXFDF-SLMZUGIISA-N 0.000 description 2
- LXZVTUDQBDJDMN-QLYXXIJNSA-N CC(/C(/C1=O)=N/Nc(cccc2-c3c[o]c(C(O)=O)c3)c2O)=NN1c1cc(CCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3c[o]c(C(O)=O)c3)c2O)=NN1c1cc(CCC2)c2cc1 LXZVTUDQBDJDMN-QLYXXIJNSA-N 0.000 description 2
- BDGGFTDRPHKXFC-QYQHSDTDSA-N CC(/C(/C1=O)=N/Nc2cccc(-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc2cccc(-c3ccc(C(O)=O)[o]3)c2O)=NN1c1cc(CCCC2)c2cc1 BDGGFTDRPHKXFC-QYQHSDTDSA-N 0.000 description 2
- LCFMHMLKNSJRNG-MKFPQRGTSA-N CC(C)(CC(C)(C)c1c2)c1ccc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O Chemical compound CC(C)(CC(C)(C)c1c2)c1ccc2N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O LCFMHMLKNSJRNG-MKFPQRGTSA-N 0.000 description 2
- WITKGWRONMFQRY-FAJYDZGRSA-N CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 Chemical compound CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3ccc(C(O)=O)[s]3)c1O)c2 WITKGWRONMFQRY-FAJYDZGRSA-N 0.000 description 2
- SGALMGILCDDTQI-GDWJVWIDSA-N CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 Chemical compound CC(C)(CC1)c2c1ccc(N(C1=O)N=C(C)/C1=N/Nc(cc(C)cc1-c3cccc(C(O)=O)c3)c1O)c2 SGALMGILCDDTQI-GDWJVWIDSA-N 0.000 description 2
- AJNGYKJVXWONGA-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc(CCCC2)c2c1 Chemical compound CC(CC1=O)=NN1c1ccc(CCCC2)c2c1 AJNGYKJVXWONGA-UHFFFAOYSA-N 0.000 description 2
- KBOGEGUAFGNMNM-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc2OCCc2c1 Chemical compound CC(CC1=O)=NN1c1ccc2OCCc2c1 KBOGEGUAFGNMNM-UHFFFAOYSA-N 0.000 description 2
- ZIWZDCCQIOCJBA-UHFFFAOYSA-N COc(c(N)ccc1)c1-c1c[nH]c(C(O)=O)c1 Chemical compound COc(c(N)ccc1)c1-c1c[nH]c(C(O)=O)c1 ZIWZDCCQIOCJBA-UHFFFAOYSA-N 0.000 description 2
- YYNNYGWARAMIBT-QDXRXGFHSA-N C/C=C\C(\c1c[nH]c(C(O)=O)c1)=C(/CN)\O Chemical compound C/C=C\C(\c1c[nH]c(C(O)=O)c1)=C(/CN)\O YYNNYGWARAMIBT-QDXRXGFHSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N C1c2ccccc2OC1 Chemical compound C1c2ccccc2OC1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- LYFGQYDJECJDQM-QLYXXIJNSA-N CC(/C(/C1=O)=N/Nc(cc(C)cc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1cc(CC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cc(C)cc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1cc(CC2)c2cc1 LYFGQYDJECJDQM-QLYXXIJNSA-N 0.000 description 1
- FIJXLXNJSOYTGV-NFFVHWSESA-N CC(/C(/C1=O)=N/Nc(cccc2-c3cc(C(O)=O)c(C)[o]3)c2O)=NN1c1cc(CCCC2)c2cc1 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3cc(C(O)=O)c(C)[o]3)c2O)=NN1c1cc(CCCC2)c2cc1 FIJXLXNJSOYTGV-NFFVHWSESA-N 0.000 description 1
- WDCBDHCATROYFF-QYQHSDTDSA-N CC(/C(/C1=O)=N/Nc(cccc2-c3cccc(C(O)=O)c3)c2O)=NN1c(cc1)cc2c1OCC2 Chemical compound CC(/C(/C1=O)=N/Nc(cccc2-c3cccc(C(O)=O)c3)c2O)=NN1c(cc1)cc2c1OCC2 WDCBDHCATROYFF-QYQHSDTDSA-N 0.000 description 1
- GMRHRUQFDAJPLL-UHFFFAOYSA-N CC(C(C1=O)N(C)Nc(cc(C)cc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1ccc(CC2)c2c1 Chemical compound CC(C(C1=O)N(C)Nc(cc(C)cc2-c3ccc(C(O)=O)[s]3)c2O)=NN1c1ccc(CC2)c2c1 GMRHRUQFDAJPLL-UHFFFAOYSA-N 0.000 description 1
- SNTLNSMWWSGMGL-UHFFFAOYSA-N CC(C(CNNc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O)C1=O)=NN1c1cc(CC2)c2cc1 Chemical compound CC(C(CNNc(cc(C)cc1-c2cccc(C(O)=O)c2)c1O)C1=O)=NN1c1cc(CC2)c2cc1 SNTLNSMWWSGMGL-UHFFFAOYSA-N 0.000 description 1
- SSJHCVPKVRRXNR-UHFFFAOYSA-N CC(C)(CC(C)(C)c1c2)c1ccc2N1N=C(C)CC1=O Chemical compound CC(C)(CC(C)(C)c1c2)c1ccc2N1N=C(C)CC1=O SSJHCVPKVRRXNR-UHFFFAOYSA-N 0.000 description 1
- VMVRYDVARIFHST-UHFFFAOYSA-N CC(C)CC(N(c1cc(CC2)c2cc1)N)=O Chemical compound CC(C)CC(N(c1cc(CC2)c2cc1)N)=O VMVRYDVARIFHST-UHFFFAOYSA-N 0.000 description 1
- JUTDHLQZZORZJS-UHFFFAOYSA-N CC(CC1)c2c1ccc(N1N=C(C)CC1=O)c2 Chemical compound CC(CC1)c2c1ccc(N1N=C(C)CC1=O)c2 JUTDHLQZZORZJS-UHFFFAOYSA-N 0.000 description 1
- GNOHBBXZXDBVPR-UHFFFAOYSA-N CC(CC1=O)=NN1C1=CC(CC2)C2C=C1 Chemical compound CC(CC1=O)=NN1C1=CC(CC2)C2C=C1 GNOHBBXZXDBVPR-UHFFFAOYSA-N 0.000 description 1
- HLSKTUANRGHHGI-UHFFFAOYSA-N CC(CC1=O)=NN1c1cc(CCC2)c2cc1 Chemical compound CC(CC1=O)=NN1c1cc(CCC2)c2cc1 HLSKTUANRGHHGI-UHFFFAOYSA-N 0.000 description 1
- FBRREKOSEGDIDA-UHFFFAOYSA-N CC(CC1=O)=NN1c1ccc(CC2)c2c1 Chemical compound CC(CC1=O)=NN1c1ccc(CC2)c2c1 FBRREKOSEGDIDA-UHFFFAOYSA-N 0.000 description 1
- LAADWVXCBDSARD-UHFFFAOYSA-N CC1(C)Cc2cc(N3N=C(C)CC3=O)ccc2C1 Chemical compound CC1(C)Cc2cc(N3N=C(C)CC3=O)ccc2C1 LAADWVXCBDSARD-UHFFFAOYSA-N 0.000 description 1
- CLSFJNMZEMHJON-UHFFFAOYSA-N CCC1c2cc(N3N=C(C)CC3=O)ccc2CC1 Chemical compound CCC1c2cc(N3N=C(C)CC3=O)ccc2CC1 CLSFJNMZEMHJON-UHFFFAOYSA-N 0.000 description 1
- QKRADKWVWPGIGH-UHFFFAOYSA-N Cc([o]c(-c(cccc1N)c1O)c1)c1C(O)=O Chemical compound Cc([o]c(-c(cccc1N)c1O)c1)c1C(O)=O QKRADKWVWPGIGH-UHFFFAOYSA-N 0.000 description 1
- SLHFGYLLIGICCB-UHFFFAOYSA-N Cc([o]c(-c(cccc1N)c1OC)c1)c1C(O)=O Chemical compound Cc([o]c(-c(cccc1N)c1OC)c1)c1C(O)=O SLHFGYLLIGICCB-UHFFFAOYSA-N 0.000 description 1
- KCMXDUNFVPYWDN-UHFFFAOYSA-N Cc([o]c(-c(cccc1[N+]([O-])=O)c1OC)c1)c1C(O)=O Chemical compound Cc([o]c(-c(cccc1[N+]([O-])=O)c1OC)c1)c1C(O)=O KCMXDUNFVPYWDN-UHFFFAOYSA-N 0.000 description 1
- HQEFZABRNVWGBR-UHFFFAOYSA-N Cc([o]c(Br)c1)c1C(OC)=O Chemical compound Cc([o]c(Br)c1)c1C(OC)=O HQEFZABRNVWGBR-UHFFFAOYSA-N 0.000 description 1
- UVRRIABXNIGUJZ-UHFFFAOYSA-N Cc([o]cc1)c1C(OC)=O Chemical compound Cc([o]cc1)c1C(OC)=O UVRRIABXNIGUJZ-UHFFFAOYSA-N 0.000 description 1
- IOTWPYBJQVUSMA-UHFFFAOYSA-O Cc(cc1)ccc1S([n]1c(C(OC)=O)cc(I)c1)([OH2+])=O Chemical compound Cc(cc1)ccc1S([n]1c(C(OC)=O)cc(I)c1)([OH2+])=O IOTWPYBJQVUSMA-UHFFFAOYSA-O 0.000 description 1
- WLYUEIAYLSVNTG-UHFFFAOYSA-N Cc(cc1N)cc(-c2ccc(C(O)=O)[s]2)c1O Chemical compound Cc(cc1N)cc(-c2ccc(C(O)=O)[s]2)c1O WLYUEIAYLSVNTG-UHFFFAOYSA-N 0.000 description 1
- UGRKXGRFPDDCFH-UHFFFAOYSA-N Cc(cc1N)cc(C2=CCC(C(O)=O)S2)c1O Chemical compound Cc(cc1N)cc(C2=CCC(C(O)=O)S2)c1O UGRKXGRFPDDCFH-UHFFFAOYSA-N 0.000 description 1
- YFGCXBAESOBLEH-UHFFFAOYSA-N Nc1cccc(-c2c[o]c(C(O)=O)c2)c1O Chemical compound Nc1cccc(-c2c[o]c(C(O)=O)c2)c1O YFGCXBAESOBLEH-UHFFFAOYSA-N 0.000 description 1
- ZXLYSSHNDUXXIN-UHFFFAOYSA-N Nc1cccc(-c2cc(C(O)=O)ccc2)c1O Chemical compound Nc1cccc(-c2cc(C(O)=O)ccc2)c1O ZXLYSSHNDUXXIN-UHFFFAOYSA-N 0.000 description 1
- MWEHFNSBOUGDRG-UHFFFAOYSA-N Nc1cccc(-c2ccc(C(O)=O)[o]2)c1O Chemical compound Nc1cccc(-c2ccc(C(O)=O)[o]2)c1O MWEHFNSBOUGDRG-UHFFFAOYSA-N 0.000 description 1
- NMSIPCUJBPZRTO-UHFFFAOYSA-N O=C(NN(C(OCC(Cl)(Cl)Cl)=O)c(cc1)cc2c1OCC2)OCC(Cl)(Cl)Cl Chemical compound O=C(NN(C(OCC(Cl)(Cl)Cl)=O)c(cc1)cc2c1OCC2)OCC(Cl)(Cl)Cl NMSIPCUJBPZRTO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810000346.6 | 2008-01-10 | ||
| CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2009/000001 WO2009092276A1 (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509263A JP2011509263A (ja) | 2011-03-24 |
| JP2011509263A5 true JP2011509263A5 (enExample) | 2012-02-23 |
| JP5441269B2 JP5441269B2 (ja) | 2014-03-12 |
Family
ID=40878665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541680A Active JP5441269B2 (ja) | 2008-01-10 | 2009-01-04 | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8367710B2 (enExample) |
| EP (1) | EP2236500B1 (enExample) |
| JP (1) | JP5441269B2 (enExample) |
| KR (1) | KR101556808B1 (enExample) |
| CN (2) | CN101481352A (enExample) |
| AU (1) | AU2009207966B2 (enExample) |
| BR (1) | BRPI0907234B1 (enExample) |
| CA (1) | CA2711535C (enExample) |
| ES (1) | ES2533366T3 (enExample) |
| MX (1) | MX2010007553A (enExample) |
| PT (1) | PT2236500E (enExample) |
| RU (1) | RU2488582C2 (enExample) |
| UA (1) | UA101172C2 (enExample) |
| WO (1) | WO2009092276A1 (enExample) |
| ZA (1) | ZA201004794B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| CN101921232A (zh) | 2009-06-11 | 2010-12-22 | 上海恒瑞医药有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用 |
| EP2492262B1 (en) * | 2009-10-23 | 2016-04-20 | Nissan Chemical Industries, Ltd. | Fused heterocyclic compound and thrombopoietin receptor activator |
| CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
| CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
| WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
| EP3116469B1 (en) | 2014-03-10 | 2018-10-03 | Mary Kay, Inc. | Skin lightening compositions |
| CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
| EP3375442A4 (en) * | 2016-01-22 | 2018-12-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising bicyclo-substituted pyrazolon azo derivative or salt thereof and preparation method thereof |
| CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
| WO2018133818A1 (zh) * | 2017-01-19 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
| CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
| US20220071961A1 (en) * | 2019-01-08 | 2022-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | Dosing Regimen of Bicyclic Substituted Pyrazolone Azo Derivative |
| CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
| WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| WO2023143364A1 (zh) * | 2022-01-25 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
| WO2025140275A1 (zh) * | 2023-12-25 | 2025-07-03 | 江苏恒瑞医药股份有限公司 | 取代吡唑啉偶氮衍生物的磷酸酯化合物或其可药用盐 |
| CN120383561A (zh) * | 2025-03-26 | 2025-07-29 | 浙江本立科技股份有限公司 | 一种三氯甲基喹啉和2-取代乙酸联产喹啉酰氯和2-取代乙酰氯的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
| GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| CN1966520B (zh) | 1995-06-07 | 2012-07-11 | 葛兰素集团有限公司 | 结合血小板生成素受体的肽和化合物 |
| JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | １，４−ベンゾジアゼピン誘導体及びその用途 |
| WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
| EP1133291B1 (en) | 1998-11-17 | 2006-01-11 | Smithkline Beecham Corporation | Cyclic polyamines for treating thrombocytopenia |
| EP1141909B1 (de) | 1998-12-14 | 2002-09-04 | Vodafone AG | Verfahren zur übertragung von verkehrsinformationen |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| KR20020069183A (ko) | 1999-07-26 | 2002-08-29 | 시오노기세이야쿠가부시키가이샤 | 트롬보포이에틴 작동성을 나타내는 의약 조성물 |
| AU770564B2 (en) | 1999-09-10 | 2004-02-26 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| JP2003513965A (ja) | 1999-11-05 | 2003-04-15 | スミスクライン・ビーチャム・コーポレイション | セミカルバゾン誘導体およびそれらのトロンボポエチン模倣物としての使用 |
| DE60031714T2 (de) | 1999-12-06 | 2007-09-06 | Smithkline Beecham Corp. | Thrombopoietin-mimetika |
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| CY2010012I2 (el) * | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| MY142390A (en) * | 2002-05-22 | 2010-11-30 | Glaxosmithkline Llc | 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
| EP1622609A4 (en) * | 2003-04-29 | 2008-09-03 | Smithkline Beecham Corp | METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS |
| EP1701934B1 (en) | 2003-12-26 | 2009-02-25 | Allergan, Inc. | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY |
| JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
| KR101215207B1 (ko) | 2004-12-14 | 2012-12-26 | 닛산 가가쿠 고교 가부시키 가이샤 | 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제 |
| WO2007044982A2 (en) * | 2005-10-13 | 2007-04-19 | Smithkline Beecham Corporation | Methods for the preservation of platelet efficacy during storage |
| CA2630234A1 (en) * | 2005-11-23 | 2007-05-31 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh not_active Ceased
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active Active
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
-
2010
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441269B2 (ja) | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 | |
| JP4546919B2 (ja) | トロンボポエチン摸倣物 | |
| JP5821079B2 (ja) | ビシクロ置換ピラゾロン−アゾ誘導体の塩、その製造方法及びその使用 | |
| EP1244446B1 (en) | Thrombopoietin mimetics | |
| AU2001274938A1 (en) | Thrombopoietin mimetics | |
| US6858630B2 (en) | Naphthimidazole derivatives and their use as thrombopoietin mimetics | |
| CN101679242B (zh) | 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2004527541A (ja) | トロンボポエチン模倣物 | |
| TWI437985B (zh) | 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用 | |
| HK1134818B (en) | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof | |
| HK1117825B (en) | Thrombopoietin mimetics |